Joanna Widdows, DO
Internal Medicine · Delray Beach, FLNPI 1619911070
Payments from drug & device makers
Across 281 payments — averaging $19.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$974
- Novo Nordisk$568
- Pfizer$486
- AbbVie$424
- Lilly USA, LLC$419
- GSK$407
- plus $2K from 24 others
What the payments were for
- Food & beverage$5,39298%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 55 | $974 |
| Novo Nordisk | 30 | $568 |
| Pfizer | 24 | $486 |
| AbbVie(2 entities) | 22 | $424 |
| Lilly USA, LLC | 23 | $419 |
| GSK | 19 | $407 |
| Astellas Pharma US Inc | 12 | $373 |
| Amarin Pharma, Inc. | 22 | $337 |
| Bayer | 8 | $188 |
| Sumitomo Pharma America, Inc. | 6 | $138 |
| Exact Sciences | 5 | $131 |
| Amgen(2 entities) | 8 | $129 |
| Alk-abello, Inc | 6 | $121 |
| Merck | 7 | $116 |
| Novartis | 5 | $96 |
| Boehringer Ingelheim | 4 | $85 |
| Inari Medical, Inc. | 2 | $71 |
| Sunovion Pharmaceuticals Inc. | 4 | $68 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $68 |
| Nevro Corp. | 2 | $57 |
| Johnson & Johnson | 2 | $41 |
| Eisai Inc. | 2 | $32 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Therapeuticsmd, Inc. | 1 | $22 |
| Almatica Pharma LLC | 1 | $20 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| Endo Pharmaceuticals Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$5,492 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 233 | $319,467 |
| JardianceEmpagliflozin | 78 | $110,740 |
| FarxigaDapagliflozin Propanediol | 79 | $107,973 |
| EliquisApixaban | 74 | $102,368 |
| MounjaroTirzepatide | 69 | $85,951 |
| TrulicityDulaglutide | 47 | $62,105 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $60,671 |
| XareltoRivaroxaban | 36 | $36,687 |
| MyrbetriqMirabegron | 38 | $34,594 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $25,405 |
| LinzessLinaclotide | 21 | $20,648 |
| RybelsusSemaglutide | 13 | $19,824 |
| Rosuvastatin Calcium | 1,738 | $17,154 |
| EntrestoSacubitril/Valsartan | 13 | $15,114 |
| Repatha SureclickEvolocumab | 12 | $13,508 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $568 | $339,291246 claims |
| Lilly USA, LLCMounjaro, Trulicity | $419 | $148,056116 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $974 | $144,083112 claims |
| Boehringer IngelheimJardiance | $85 | $110,74078 claims |
| PfizerEliquis, Prempro | $486 | $104,84885 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $407 | $86,35187 claims |
| Johnson & JohnsonXarelto | $41 | $36,68736 claims |
| Astellas Pharma US IncMyrbetriq | $373 | $34,59438 claims |
| AbbVieLinzess, Synthroid | $424 | $31,933156 claims |
| NovartisEntresto | $96 | $15,11413 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $138 | $13,35317 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $18 | $7,747889 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Delray Beach
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.